Zhao L - Search Results

1

⁶⁸Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer.

Zhao L, Chen S, Chen S, Pang Y, Dai Y, Hu S, Lin L, Fu L, Sun L, Wu H, Chen H, Lin Q. Zhao L, et al. Radiother Oncol. 2021 May;158:55-61. doi: 10.1016/j.radonc.2021.02.015. Epub 2021 Feb 20. Radiother Oncol. 2021. PMID: 33621587 Free article.

2

68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal Cancer.

Chen H, Zhao L, Ruan D, Sun L, Lin Q. Chen H, et al. Among authors: zhao l. Clin Nucl Med. 2020 Jun;45(6):468-470. doi: 10.1097/RLU.0000000000003000. Clin Nucl Med. 2020. PMID: 32149789

3

Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Chen H, et al. Among authors: zhao l. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28. Eur J Nucl Med Mol Imaging. 2020. PMID: 32222810

4

68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient.

Zhao L, Gu J, Fu K, Lin Q, Chen H. Zhao L, et al. Clin Nucl Med. 2020 Oct;45(10):e430-e432. doi: 10.1097/RLU.0000000000003015. Clin Nucl Med. 2020. PMID: 32332301

5

[⁶⁸Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer.

Zhao L, Chen S, Lin L, Sun L, Wu H, Lin Q, Chen H. Zhao L, et al. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3188-3189. doi: 10.1007/s00259-020-04818-7. Epub 2020 Apr 24. Eur J Nucl Med Mol Imaging. 2020. PMID: 32333070 No abstract available.

6

68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer.

Pang Y, Huang H, Fu L, Zhao L, Chen H. Pang Y, et al. Among authors: zhao l. Clin Nucl Med. 2020 Aug;45(8):632-635. doi: 10.1097/RLU.0000000000003099. Clin Nucl Med. 2020. PMID: 32453079

7

Usefulness of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [¹⁸F]FDG PET/CT findings.

Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, Wu X, Guo W, Fan C, Wu J, Huang W, Lin Q, Sun L, Wu H. Chen H, et al. Among authors: zhao l. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):73-86. doi: 10.1007/s00259-020-04940-6. Epub 2020 Jun 25. Eur J Nucl Med Mol Imaging. 2021. PMID: 32588089

8

68Ga-FAPI Outperforms 18F-FDG PET/CT in Identifying Bone Metastasis and Peritoneal Carcinomatosis in a Patient With Metastatic Breast Cancer.

Pang Y, Zhao L, Chen H. Pang Y, et al. Among authors: zhao l. Clin Nucl Med. 2020 Nov;45(11):913-915. doi: 10.1097/RLU.0000000000003263. Clin Nucl Med. 2020. PMID: 32910045

9

Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [⁶⁸Ga]Ga-FAPI-04 PET/CT versus MRI and [¹⁸F]-FDG PET/CT.

Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Guo W, et al. Among authors: zhao l. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1604-1617. doi: 10.1007/s00259-020-05095-0. Epub 2020 Nov 11. Eur J Nucl Med Mol Imaging. 2021. PMID: 33179149

10

68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma.

Pang Y, Wei J, Shang Q, Zhao L, Chen H. Pang Y, et al. Among authors: zhao l. Clin Nucl Med. 2021 Feb 1;46(2):177-179. doi: 10.1097/RLU.0000000000003454. Clin Nucl Med. 2021. PMID: 33315682

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34,776 results

Search Page